
Sanjivani Paranteral Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
No
Order
N/A
Capex
No
0 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Base business expected to grow at approximately 25% year-on-year.
- HAL joint venture projected to contribute one quarter of revenue in FY ‘25 and a full year in FY ‘26.
- Prague joint venture operational with initial orders executed; full operational capacity expected by end of August or September 2024.
- Growth from strategic partnerships with five state PSUs and potential expansion via Public-Private Partnership (PPP) models.
- Expansion into new geographies including Africa, Central America, Middle East, and Latin America.
- Focus on complex products and higher value-addition segments, with plans to grow injectable segment alongside nutraceuticals via Prague.
- Logistics and geopolitical uncertainty (e.g., Middle East tensions) present challenges affecting order flow and costs.
- No major immediate funding required; prior preferential raise funded January 2024 projects.
See what Sanjivani Paranteral management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- Currently, Sanjivani Paranteral Limited has no debt on its books and plans to maintain a debt-free status.
- There are no ongoing plans or requirements for new debt funding.
- Regarding equity or other funding for future investments, no additional funds are needed at present.
- Recent projects mentioned were funded earlier in January through a preferential equity raise, as disclosed in Stock Exchange documents.
- No immediate fundraising activities are planned since existing funds cover current projects, and no new opportunities requiring funding have been identified.
See what Sanjivani Paranteral management said on order book — free account, 30 seconds.
Capex plans
No- The company currently does not require additional funds for projects; recent investments were raised through a preferential raise in January.
- For the base business growth (around 20-25% YoY), no major incremental CAPEX is expected beyond ongoing maintenance and upgrades.
- Planned CAPEX of Rs. 10-12 crores is for basic upgrades and regulatory inspections, spread over this and next financial year, not as an annual recurring expense.
- The HAL Joint Venture has a development timeline of 9-12 months for production start, with commercial operations expected by October 2024.
- The Prague JV is partially operational, with full-scale operations anticipated by end of August or September 2024.
- The company is exploring strategic partnerships, mainly with government PSUs and potential collaborations in oncology and hormone therapeutic areas, though no immediate new collaborations confirmed.
Track Sanjivani Paranteral — get its next earnings analysis in your feed
How does Sanjivani Paranteral rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Sanjivani Paranteral rank in Pharmaceuticals & Biotechnology?
Compare Sanjivani Paranteral against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Sanjivani Paranteral's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem